<DOC>
	<DOCNO>NCT01300546</DOCNO>
	<brief_summary>This study conduct evaluate hypothesis use pharmacological non-pharmacological intervention may allow subject high risk chronic migraine avoid reverse transformation episodic migraine chronic migraine .</brief_summary>
	<brief_title>Treximet Trademark ( TM ) Prevention Modification Disease Progression Migraine</brief_title>
	<detailed_description>Two investigative center enroll 40 subject United States . Subject participation 5 visit study last 4 month . At Visit 1 , follow informed consent , medical , migraine , medication history collect physical neurological exam vital sign perform . An electrocardiogram ( ECG ) complete . A Lifestyle Choices Better Migraine Management Questionnaire ( Lifestyle Questionnaire ) complete . Eligible subject complete 1-month Baseline Period treat migraine current preferred treatment choice , document headache severity associate symptom 30-day Baseline Diary . At Visit 2 , Baseline Diary review pregnancy test collect subject childbearing potential . Vital sign collect Adverse Events document . Subjects continue meet eligibility criterion randomize 1:1 Treximet naproxen provide study medication treat 14 few day per month . Subjects encourage treat migraine attack within 1 hour onset headache pain pain still mild . Subjects view educational digital video disc ( DVD ) concern lifestyle modification , receive copy home viewing , complete Lifestyle Questionnaire , receive 3 copy Lifestyle Questionnaire weekly completion Visits 2 3 . The Migraine Disability Assessment questionnaire ( MIDAS ) complete 30-day Treatment Period Diary dispense . At Visits 3 4 , Adverse Events collect , complete Diaries review , Drug Accountability perform . Pregnancy test collect subject childbearing potential . Vital sign collect . Completed Lifestyle Questionnaires collect , Lifestyle Questionnaire complete office , 3 copy dispense weekly completion visit . Study medication follow month dispense 30-day Diary . At Visit 5 , Adverse Events collect , complete Diaries review , Drug Accountability perform . Pregnancy test collect subject childbearing potential . Vital sign collect . Completed Lifestyle Questionnaires collect Lifestyle Questionnaire complete office . Subjects complete MIDAS exiting study .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject Is male female , otherwise good health , 18 65 year age . Has history frequent episodic migraine ( 614 migraine day per month ) ( without aura ) accord 2nd Edition The International Headache Classification ( ICHD2 ) least 3 month . ( Stage 23 frequent transform migraine ) Had onset migraine age 50 . Is able differentiate migraine headache may experience ( e.g. , tensiontype headache ) . Has stable history headache least 3 month prior screen . Is currently take migraine preventive take preventive least 30 day prior screen agrees start , stop , change medication and/or dosage study period . Has least 50 % migraine attack begin mild severity . If female childbearing potential , negative urine pregnancy test Visits 15 us , agrees use , duration study , medically acceptable form contraception determine investigator . 1 . Complete abstinence intercourse 2 week prior administration study drug throughout study , time interval completion premature discontinuation study account elimination study drug ( minimum 7 day ) ; , 2 . Surgically sterile ( hysterectomy tubal ligation otherwise incapable pregnancy ) ; , 3 . Sterilization male partner ; , 4 . Intrauterine device publish data show low expected failure rate le 1 % per year ; , 5 . Double barrier method ( i.e. , 2 physical barrier OR 1 physical barrier plus spermicide ) least 1 month prior Visit 1 throughout study ; , 6 . Hormonal contraceptive least 3 month prior Visit 1 throughout study . Had 6 migraine treatment day 1 month prior Visit 2 . Subject Is unable understand study requirement , informed consent , complete headache record require per protocol . Is pregnant , actively try become pregnant , breastfeed . Has experience follow migraine variant : basilar migraine , aura without headache , familial hemiplegic migraine , complicate migraine , ophthalmoplegic migraine retinal migraine . Has history Medication Overuse Headache 3 month prior study enrollment baseline phase Has history acute migraine treatment great than14 day per month 3 month prior screen . Has abuse , opinion Investigator , follow drug , currently within past 1 year : 1. opioids 2. alcohol 3. barbiturates 4. benzodiazepine 5. cocaine Has history impair hepatic renal function , investigator 's opinion , contraindicate participation study . Has unstable neurological condition significantly abnormal neurological examination focal sign sign increase intracranial pressure . Suffers cardiovascular disease ( ischemic heart disease , include angina pectoris , myocardial infarction , document silent ischemia , Prinzmetal 's angina ) ; symptom ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome ; uncontrolled hypertension ( â‰¥140/90 millimeter mercury ( mmHg ) 2 3 blood pressure ( BP ) measurement screen ) ; electrocardiogram ( ECG ) result outside normal limit clinically stable patient judge investigator . Has history asthma nasal polyp . Has history peptic ulcer disease require therapeutic intervention year prior study enrollment Has evidence history gastrointestinal ( GI ) surgery GI ulceration perforation stomach intestine past 6 month , gastrointestinal bleeding past year evidence history inflammatory bowel disease history bleed disorder , take plan take anticoagulant antiplatelet agent within 2 week prior screen 48 hour post final study treatment . Has history nonsteroidal antiinflammatory drug induce gastritis , esophagitis , duodenitis . Suffers serious illness , unstable medical condition , one could require hospitalization , could increase risk adverse event . Has opinion investigator significant cardiovascular risk profile may include uncontrolled high blood pressure , postmenopausal woman , male 40 year old , hypercholesterolemia , obesity , diabetes mellitus , smoking , family history cardiovascular disease 1st degree relative . Has opinion investigator significant cerebrovascular risk profile may include female age 35 use oral birth control , smoking , family history cerebrovascular disease first degree relative . Has psychiatric condition , opinion investigator may affect interpretation efficacy safety data contraindicates subject 's participation study . Has hypersensitivity , intolerance , contraindication use sumatriptan , component , 5hydroxytryptamine 1 ( 5HT1 ) agonist . Has hypersensitivity , intolerance , contraindication use naproxen , component , nonsteroidal antiinflammatory drug include aspirin cyclooxygenase2 ( COX2 ) inhibit agent . Is currently take migraine prophylactic medication contain ergotamine ergot derivative dihydroergotamine ( DHE ) methysergide . Has take , plan take , monoamine oxidase inhibitor ( MAOI ) include herbal preparation contain St. John 's wort ( Hypericum perforatum ) , anytime within 2 week prior screen 2 week post final study treatment . Has take plan take angiotensinconverting enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) anytime within 2 week prior screen 48 hour post final study treatment . Has receive investigational agent within 30 day prior Visit 1 . Plans participate another clinical study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Frequent migraine</keyword>
	<keyword>Migraine transformation</keyword>
	<keyword>Migraine</keyword>
	<keyword>Treximet</keyword>
	<keyword>Naproxen</keyword>
	<keyword>Sumatriptan</keyword>
</DOC>